Anticancer research · 2025
Efficacy of Lenvatinib and Atezolizumab Bevacizumab Combination Therapy in Patients With Combined Hepatocellular-cholangiocarcinoma.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tanabe Norikazu, Saeki Issei, Yamaoka Kenji, Kawaoka Tomokazu, Tomonari Tetsu, Tani Joji, Terashima Takeshi, Kawamura Yusuke, Oka Shiro, Takayama Tetsuji, Kobara Hideki, Yamashita Taro, Akuta Norio, Yamasaki Takahiro, Takami Taro
Аннотация
BACKGROUND/AIM: Surgical resection remains the only curative treatment for combined hepatocellular-cholangiocarcinoma; however, systemic therapy is the primary treatment option for unresectable cases. This multicenter retrospective study aimed to assess the efficacy of systemic therapy for unresectable combined hepatocellular-cholangiocarcinoma.
PATIENTS AND METHODS: Twenty-one patients with histologically confirmed or clinically diagnosed combined hepatocellular-cholangiocarcinoma who received systemic therapy were included. First-line regimens consisted of lenvatinib (n=14) and atezolizumab plus bevacizumab (n=7) and their therapeutic efficacy was evaluated.
RESULTS: The objective response and disease control rates were 42.9% and 92.9% for lenvatinib, and 14.3% and 100% for atezolizumab plus bevacizumab, respectively. Median overall survival for all treatments was 14.9 months and median progression-free survival was 6.5 months. By regimen, median overall and progression-free survival was 14.9 and 6.1 months for lenvatinib, and "not reached" and 7.9 months for atezolizumab plus bevacizumab, respectively.
CONCLUSION: Lenvatinib and atezolizumab plus bevacizumab exhibited potential activity in patients with combined hepatocellular-cholangiocarcinoma.
PATIENTS AND METHODS: Twenty-one patients with histologically confirmed or clinically diagnosed combined hepatocellular-cholangiocarcinoma who received systemic therapy were included. First-line regimens consisted of lenvatinib (n=14) and atezolizumab plus bevacizumab (n=7) and their therapeutic efficacy was evaluated.
RESULTS: The objective response and disease control rates were 42.9% and 92.9% for lenvatinib, and 14.3% and 100% for atezolizumab plus bevacizumab, respectively. Median overall survival for all treatments was 14.9 months and median progression-free survival was 6.5 months. By regimen, median overall and progression-free survival was 14.9 and 6.1 months for lenvatinib, and "not reached" and 7.9 months for atezolizumab plus bevacizumab, respectively.
CONCLUSION: Lenvatinib and atezolizumab plus bevacizumab exhibited potential activity in patients with combined hepatocellular-cholangiocarcinoma.
Предметные рубрики MeSH
AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBile Duct NeoplasmsCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsPhenylurea CompoundsProgression-Free SurvivalQuinolinesRetrospective StudiesTreatment Outcome